N-acetylprocainamide Antibody (901): sc-66070

N-acetylprocainamide Antibody (901) is a mouse monoclonal IgG1 antibody that detects N-acetylprocainamide protein of non-species reactive by enzyme-linked immunosorbent assay (ELISA). N-acetylprocainamide (901) antibody is available as a non-conjugated antibody. Procainamide, commonly known by its brand names Pronestyl, Procanbid, or Procan, is a class Ia antiarrhythmic drug utilized in the management of cardiac arrhythmias, administered either orally or intravenously. The mechanism of action of Procainamide involves the blockade of open sodium channels, which prolongs the cardiac action potential and slows conduction, making N-acetylprocainamide crucial for stabilizing heart rhythm. N-acetylprocainamide, the active metabolite of Procainamide, exhibits a stronger pharmacological effect and is primarily eliminated through renal pathways. Understanding N-acetylprocainamide interactions with specific proteins is vital, as these interactions can influence drug efficacy and safety profile. N-acetylprocainamide has been shown to interact with various ion channels and proteins involved in cardiac function, which can lead to significant clinical implications, including potential adverse effects such as myalgia, rash, and hypersensitivity reactions, including agranulocytosis and fever. N-acetylprocainamide may trigger autoimmune responses, resulting in systemic lupus erythematosus-like symptoms, underscoring the importance of monitoring patients receiving this treatment.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

N-acetylprocainamide Antibody (901) References:

1. Combined high-efficiency hemodialysis and charcoal hemoperfusion in severe N-acetylprocainamide intoxication.  |  Kar, PM., et al. 1992. Am J Kidney Dis. 20: 403-6. PMID: 1384320
2. Transport of procainamide in a kidney epithelial cell line LLC-PK1.  |  Takano, M., et al. 1992. Biochim Biophys Acta. 1108: 133-9. PMID: 1637838
3. Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.  |  Harron, DW. and Brogden, RN. 1990. Drugs. 39: 720-40. PMID: 1693889
4. Procainamide, but not N-acetylprocainamide, induces protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis.  |  Siraki, AG., et al. 2008. Chem Res Toxicol. 21: 1143-53. PMID: 18489081
5. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.  |  Kim, SY. and Benowitz, NL. 1990. Drug Saf. 5: 393-420. PMID: 2285495
6. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.  |  Funck-Brentano, C., et al. 1989. J Cardiovasc Pharmacol. 14: 364-73. PMID: 2476614
7. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.  |  Giardina, EG. 1984. Ann N Y Acad Sci. 432: 177-88. PMID: 6084435
8. Clinical pharmacokinetics of N-acetylprocainamide.  |  Connolly, SJ. and Kates, RE. 1982. Clin Pharmacokinet. 7: 206-20. PMID: 6178545
9. N-acetyl procainamide causing torsades de pointes.  |  Olshansky, B., et al. 1982. Am J Cardiol. 50: 1439-41. PMID: 6183970
10. Procainamide: a perspective on its value and danger.  |  Ellenbogen, KA., et al. 1993. Heart Dis Stroke. 2: 473-6. PMID: 8137053
11. Dual actions of procainamide on batrachotoxin-activated sodium channels: open channel block and prevention of inactivation.  |  Zamponi, GW., et al. 1993. Biophys J. 65: 2324-34. PMID: 8312472
12. Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.  |  Dutcher, JS., et al. 1977. Clin Pharmacol Ther. 22: 447-57. PMID: 902457